Millenium Pharma to Evaluate Horizon Discovery's Human and Mutant Cell Lines | GenomeWeb
NEW YORK (GenomeWeb News) – Horizon Discovery said today that Millenium Pharmaceuticals will evaluate seven of Horizon’s X-MAN normal and mutant isogenic cell lines during an eight-month period.
 
The X-MAN cell lines may help speed the discovery of personalized cancer medicine, the company said. These cell lines are genetically defined in vitro models of human cancer and their matched normal cell types. They include a set of double cancer-gene "knock-in" lines designed to evaluate patient resistance to targeted agents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.